Comparison of extended-release Niacin and Atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

American Journal of Cardiology

Volumn 89, Issue 11, 2002, Pages 1306-1308

  Van, Joanne T ^a   Pan, Jianqiu ^a   Wasty, Talat ^a   Chan, Eve ^a   Wu, Xiaoshan ^a   Charles, M Arthur ^a,b  

^a Diabetes Research Center   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; NIACIN; PYRROLES; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0036606905     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02333-0     Document Type: Article

References (20)

1. Successful treatment of the atherogenic lipid profile and Lp(a) in diabetic patients using niacin
2. Extended release niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
3. The atherogenic lipid profile is associated with type 2 diabetes and some of its treatment modalities
4. The atherogenic lipid phenotype and Lp(a) in diabetes
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel of detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
6. Position statement. Management of dyslipidemia in adults with diabetes
7. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
8. Troglitiazone and small low-density lipoprotein in type 2 diabetes
9. For the worldwide expanded dose simvastatin study group: Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolemia
10. Effect of fluvastatin on low-density lipoprotein peak particle diameter
11. The effect of aggressive verus standard lipid lowering by atorvastatin on diabetic dyslipidemia
12. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
13. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
14. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects
15. Mechanism of action of niacin on lipoprotein metabolism
16. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects
17. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
18. Lipoprotein heterogeneity and apolipoprotein B metabolism
19. Atorvastatin therapy ameliorates diabetic dyslipidemia by increasing lipoprotein lipase activity (abstr)